Erectile Dysfunction in Male Patients with Multiple System Atrophy

Male patients with multiple system atrophy may experience erectile dysfunction as part of the condition's autonomic involvement. Managing it in this setting requires a specific evidence-based approach that accounts for the haemodynamic context of the disease.

Clinical scenario: Male patients diagnosed with multiple system atrophy who have difficulty achieving or maintaining an erection. The autonomic features of this neurodegenerative condition directly shape which therapeutic options are appropriate and how they must be applied safely.

Treatment approach

Evidence supports use of a phosphodiesterase type 5 inhibitor for this indication. Because agents in this class can produce significant effects on systemic blood pressure, the full protocol details the necessary clinical context and considerations — only a structured approach captures the complete picture.

Instant Access to Structured Evidence-Based Regimens

References

Sildenafil, a phosphodiesterase type 5 inhibitor, improved erectile dysfunction in a small, randomized, placebo-controlled trial in men with multiple system atrophy.

Other phosphodiesterase type 5 inhibitors can also be used for erectile dysfunction (tadalafil or vardenafil).

DOI: 10.1212/cont.0000000000001598

View source ↗